The study demonstrates that a novel formulation of sodium valproate – incorporating both immediate-release and sustained-release components – achieves stable plasma concentrations that are crucial for effective inhibition of histone deacetylases (HDAC). These results further support an improved dosing regimen for VAL00, Respiratorius’ lead candidate being developed for first-line treatment of diffuse large B-cell lymphoma (DLBCL) in combination with R-CHOP.

“This publication is an important scientific milestone and external validation of our development strategy,” said Johan Drott, CEO of Respiratorius. “Being published in a respected journal highlights the robustness of our HDAC inhibition platform and reinforces the potential of VAL001 as a novel epigenetic therapy in oncology.”

The acceptance of this manuscript underscores Respiratorius’ commitment to high-quality research and strengthens its scientific presence in the field of clinical pharmacology and oncology drug development.

For further information, please contact:

About Respiratorius

Respiratorius AB (publ) is developing candidates for new effective drugs for the treatment of aggressive lymphoma. The company's business concept is to develop candidates for new drugs based on patent-pending substances, which in preclinical studies have shown superior results compared to what is currently considered standard treatment. For more information about Respiratorius, visit www.respiratorius.com.

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-04-2025 10:31 CET.